Frontiers in Oncology (Aug 2022)

131I-Caerin 1.1 and 131I-Caerin 1.9 for the treatment of non-small-cell lung cancer

  • Na Liu,
  • Tiantian He,
  • Zewei Xiao,
  • Juan Du,
  • Keke Zhu,
  • Xiongying Liu,
  • Tongsheng Chen,
  • Wenjuan Liu,
  • Guoying Ni,
  • Xiaosong Liu,
  • Xiaosong Liu,
  • Tianfang Wang,
  • Tianfang Wang,
  • Jiangtao Quan,
  • Jinhe Zhang,
  • Peipei Zhang,
  • Jianwei Yuan

DOI
https://doi.org/10.3389/fonc.2022.861206
Journal volume & issue
Vol. 12

Abstract

Read online

ObjectiveTo investigate the effect of the 131I-labeled high-affinity peptides Caerin 1.1 and Caerin 1.9 for the treatment of A549 human NSCLC cells.Methods① 3-[4,5-Dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and plate clone formation assays were performed to confirm the in vitro anti-tumor activity of Caerin 1.1 and Caerin 1.9. ② Chloramine-T was used to label Caerin 1.1 and Caerin 1.9 with 131I, and the Cell Counting Kit 8 assay was performed to analyze the inhibitory effect of unlabeled Caerin 1.1, unlabeled Caerin 1.9, 131I-labeled Caerin 1.1, and 131I-labeled Caerin 1.9 on the proliferation of NSCLC cells. An A549 NSCLC nude mouse model was established to investigate the in vivo anti-tumor activity of unlabeled Caerin 1.1, unlabeled Caerin 1.9, 131I-labeled Caerin 1.1, and 131I-labeled Caerin 1.9.Results① Caerin 1.1 and Caerin 1.9 inhibited the proliferation of NSCLC cells in vitro in a concentration-dependent manner. The half-maximal inhibitory concentration was 16.26 µg/ml and 17.46 µg/ml, respectively, with no significant intergroup difference (P>0.05). ② 131I-labeled Caerin 1.1 and 131I-labeled Caerin 1.9 were equally effective and were superior to their unlabeled versions in their ability to inhibit the proliferation and growth of NSCLC cells (P>0.05).Conclusions131I-labeled Caerin 1.1 and 131I-labeled Caerin 1.9 inhibit the proliferation and growth of NSCLC cells and may become potential treatments for NSCLC.

Keywords